etretinate
Sign in to saveAlso known as Ro-109359, Tegison®, Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate, Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate, 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethyl ester
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.
Research
3,808 papers- Etretinate therapy.Journal of the American Academy of Dermatology · 1987
- Etretinate and psoriasis.Archives of dermatology · 1987
- Etretinate. A clinician's view.Dermatologic clinics · 1988
- Teratogenic risk with etretinate and acitretin treatment.Dermatology (Basel, Switzerland) · 1994
- Pharmacokinetics of acitretin and etretinate.Journal of the American Academy of Dermatology · 1998
via PubMed
~3 min read
Encyclopedic overview
6 sectionsContents
- Pharmacology
- Precautions
- Side effects
- History
- See also
- References
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.
==Pharmacology== Etretinate is a highly lipophilic, aromatic retinoid. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy. Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days, which make dosing difficult.
Excerpted from Wikipedia’s “etretinate” article, available under the CC BY-SA 4.0 licence.